

Supplementary Table 1 – Clinical characteristics of the included patients

Age (years), mean (SD)	67 (±8.4)
Female sex, n (%)	99 (55%)
BMI (kg/m ²), mean (SD)	25.8 (±5.4)
Smoking status:	
Former Smoker	124 (69%)
Current Smoker	56 (31%)
Tobacco Exposure (Pack Years)	43.4 (±18.6)
Inhaled medication:	
ICS use, n (%)	78 (43%)
Dual bronchodilator therapy, n (%)	49 (27%)
Triple therapy, n (%)	66 (37%)
Exacerbations, n (%)	61 (34%)
Frequent exacerbations (≥2 p.a.), n (%)	38 (21%)
Atopy (n=178), n (%)	32 (18%)
SNOT22 (0-110), median (IQR)	19 (10-29)
SNOT22 _{UAS} (0-35), median (IQR)	4 (1-9)
CAT score	16 (±7.1)
GOLD stage, n (%)	
A	33 (18%)
B	98 (54%)
C	4 (2%)
D	45 (25%)
Lung function tests	
FEV1 (L), mean (SD)	1.4 (±0.6)
FEV1 % predicted, mean (SD)	53 (±17)
FVC (L), mean (SD)	2.8 (±0.93)
FVC % predicted, mean (SD)	84 (±18)
RV (L), mean (SD)	4.5 (±1.41)
RV % predicted, mean (SD)	197 (±63)
TLC (L), mean (SD)	7.0(±1.6)
TLC % predicted, mean (SD)	119 (±22)
DLCO (mmol/min/kPa), mean (SD)	4.1 (±1.8)
DLCO % predicted, mean (SD)	50 (±19)
BMI: Body Mass index, SNOT22: Sino Nasal outcome Test 22, CAT: COPD Assessment Test, ICS: Inhaled corticosteroid, FEV1: Forced Expirations Volume 1 second, FVC: Forced Expiratory Volume, RV: Residual Volume, TLC: Total Lung Capacity, DLCO: Diffusion Capacity Carbon Monoxide.	